Phocas Financial Corp. Reduces Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Phocas Financial Corp. trimmed its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 0.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 75,285 shares of the specialty pharmaceutical company’s stock after selling 419 shares during the period. Phocas Financial Corp. owned 0.42% of ANI Pharmaceuticals worth $4,053,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ridgewood Investments LLC bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at about $53,000. Lazard Asset Management LLC bought a new stake in ANI Pharmaceuticals during the 4th quarter valued at about $55,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ANI Pharmaceuticals by 79.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,421 shares of the specialty pharmaceutical company’s stock valued at $56,000 after purchasing an additional 627 shares in the last quarter. Systematic Financial Management LP bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at about $68,000. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in ANI Pharmaceuticals during the 3rd quarter valued at about $71,000. 69.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ANIP shares. TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Thursday, August 10th. HC Wainwright lifted their price target on shares of ANI Pharmaceuticals from $60.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday, August 22nd. Truist Financial reaffirmed a “buy” rating and set a $70.00 price target on shares of ANI Pharmaceuticals in a report on Monday, August 21st. Guggenheim reissued a “buy” rating and issued a $72.00 target price on shares of ANI Pharmaceuticals in a report on Wednesday, September 13th. Finally, StockNews.com began coverage on shares of ANI Pharmaceuticals in a report on Thursday, August 17th. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $71.67.

ANI Pharmaceuticals Stock Down 0.9 %

Shares of ANIP stock traded down $0.54 during trading hours on Tuesday, reaching $60.89. 31,869 shares of the stock were exchanged, compared to its average volume of 119,713. The firm has a market capitalization of $1.24 billion, a P/E ratio of -127.02 and a beta of 1.05. ANI Pharmaceuticals, Inc. has a 12-month low of $30.53 and a 12-month high of $65.89. The business’s fifty day moving average is $58.05 and its two-hundred day moving average is $48.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.74 and a quick ratio of 2.89.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.64. ANI Pharmaceuticals had a positive return on equity of 15.77% and a negative net margin of 1.29%. The business had revenue of $116.50 million during the quarter, compared to the consensus estimate of $99.87 million. During the same period in the prior year, the company earned ($0.05) earnings per share. The company’s revenue was up 57.6% compared to the same quarter last year. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.2 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Antonio R. Pera sold 3,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $60.37, for a total value of $181,110.00. Following the completion of the transaction, the director now owns 33,627 shares in the company, valued at $2,030,061.99. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Antonio R. Pera sold 3,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $60.37, for a total transaction of $181,110.00. Following the completion of the sale, the director now owns 33,627 shares in the company, valued at approximately $2,030,061.99. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Muthusamy Shanmugam sold 5,969 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $51.48, for a total value of $307,284.12. Following the sale, the chief operating officer now owns 1,250,120 shares of the company’s stock, valued at approximately $64,356,177.60. The disclosure for this sale can be found here. Insiders sold a total of 470,533 shares of company stock valued at $27,138,307 over the last three months. 28.50% of the stock is currently owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products.